Obesity and asthma

Miethe, Sarah; Karsonova, Antonina; Karaulov, Alexander; Renz, Harald

doi:10.1016/j.jaci.2020.08.011

Cited by 118 publications

(92 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Obesity significantly reduces the level of general and specific LQ of people with asthma, especially in the spheres of physical and social functions [18,19]. All the above-mentioned allow considering obesity in asthma patients to be one of the main reasons for the LQ worsening [20].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the obesity influence on the life quality in patients with bronchial asthma

et al. 2021

View full text Add to dashboard Cite

The obese asthma is characterized by a more severe course. The feature of this comorbid condition is the reduced effectiveness of basic therapy with inhaled corticosteroids, which prevents optimal control of symptoms, requires increasing doses and increases the number of exacerbations and hospitalizations. The problem of life quality (LQ) research in patients with asthma and obesity is highly relevant today, which made it the reason for this study. The aim of the study was to determine the effect of obesity on LQ in patients with asthma. Materials and methods. We selected for participating in the study 46 patients with moderate severity asthma. Examination of the patients included: objective examination with an anthropometric evaluation, the test of the LQ with two questionnaires: general one – Medical Outcome Study SF-36 (MOS SF-36) and specialized Asthma Quality of Life Questionnaire (AQLQ). Results. The increase in body mass index (BMI) in patients with asthma according to the questionnaires MOS SF-36 and AQLQ is associated with significant reductions in viability (r=–0.33, p<0.05), physical activity (r=–0.37, p<0.01), social activity (r=–0.36, p <0.01) and the degree of reduction of the patient's tolerance to adverse environmental factors (r=–0.29, p<0.05) Conclusions. The presence of concomitant obesity in patients with asthma is associated with significant reductions in the parameters of physical and social activity, viability and with an increase in the subjective pain assessment (according to the questionnaire MOS SF-36) and characterized by significantly lower rates of activity, tolerance to adverse environmental factors and general life quality (according to the AQLQ questionnaire).

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the obesity influence on the life quality in patients with bronchial asthma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The pathogenic link between obesity and asthma, as well as the concept of obesity-related asthma, has recently been fully recognized, and is characterized by pronounced respiratory symptoms and relative unresponsiveness to standardized treatment regimens (1). Weight loss through lifestyle modifications (e.g., dieting and exercise) or surgery (e.g., laparoscopic adjustable gastric banding) significantly improves lung function, asthma control, and quality of life (2,3).…”

Section: Introductionmentioning

confidence: 99%

“…Weight loss through lifestyle modifications (e.g., dieting and exercise) or surgery (e.g., laparoscopic adjustable gastric banding) significantly improves lung function, asthma control, and quality of life (2,3). Although multiple factors underlying the mechanisms of obese asthma have been widely explored and proposed over recent decades, which involve mechanical factors (e.g., reduction in functional residual capacity), inflammation (e.g., altered airway inflammation and chronic low-grade systemic inflammation), and the immune-metabolic axis (e.g., microbial dysbiosis, mitochondrial dysfunction, free fatty acid metabolism, and glucagon-like peptide pathway), numerous questions remain to be answered (1).…”

Section: Introductionmentioning

confidence: 99%

“…Inhaled corticosteroids (ICS), in view of their strong anti-inflammatory effects, have long been regarded as the mainstay of asthma maintenance treatment, with no other anti-inflammatory drugs superior enough to challenge its therapeutic position. However, compared with lean asthmatics, a higher proportion of patients with obesity demonstrate unresponsiveness even to regimens containing high doses of ICS or oral corticosteroids and fail to achieve good asthma control (1), leading to a pressing demand for the emergence of promising new therapeutic options for this subgroup of patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Linggan Wuwei Jiangxin formula ameliorates airway hyperresponsiveness through suppression of IL-1β and IL-17A expression in allergic asthmatic mice especially with diet-induced obesity

Xue

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Obese asthma represents a disease phenotype, which is associated with worse disease control and unresponsiveness to standard anti-inflammatory regimens, including inhaled corticosteroids. Obesityrelated innate airway hyperresponsiveness (AHR) plays a role in this asthma phenotype via activation of the IL-1β/innate lymphoid cell 3 (ILC3)/IL-17A pathway. Linggan Wuwei Jiangxin (LGWWJX) formula may be a promising therapeutic option for obese asthma according to traditional Chinese medicine theory, clinical experience and related research.Methods: The murine model of allergic asthma with obesity was induced by ovalbumin (OVA) sensitization and challenge in combination with a high fat diet (HFD). LGWWJX formula intervention was oral administrated. AHR and bronchoalveolar lavage fluid (BALF) cellularity were measured. Lung and liver histopathology assessment was performed by haematoxylin and eosin (H&E) staining. IL-1β and IL-17A in BALF and serum were evaluated by ELISA. Additionally, the influence of different concentrations ofLGWWJX formula on IL-1β stimulated IL-17A mRNA expression in ILC3 cells was evaluated in vitro. Results:LGWWJX treatment significantly reduced AHR and allergic airway inflammatory responses in asthmatic mice, as measured by pulmonary histopathology and BALF cellularity, and these effects were more pronounced in obese asthmatic mice. While eosinophil infiltration in BALF was suppressed withLGWWJX treatment in non-obese asthmatic mice, neutrophils and basophils were significantly decreased in obese asthmatic mice. Notably, LGWWJX also demonstrated remarkable efficacy for weight loss and improvements in hepatic steatosis in mice fed with a HFD. Furthermore, the protein levels of IL-1β in both serum and BALF, as well as those of BALF IL-17A, declined with LGWWJX intervention in both obese and non-obese asthmatic mice, and results from ex-vivo experiments found that LGWWJX significantly attenuated the expression of IL-17A in ILC3 cells with or without stimulation by IL-1β. Conclusions:LGWWJX may exert a protective effect on asthmatic individuals, especially those with concurrent obesity, most likely through mechanisms including the inhibition of the IL-1β/ILC3/IL-17A/ AHR axis, anti-inflammatory effects, weight loss, and the regulation of lipid metabolism. This suggests a promising role of LGWWJX, alone or in combination with anti-inflammatory agents, for the treatment of obese asthma.

show abstract

“…The mortality rates of this disease have declined recently. However, there are still some associated comorbidities, such as systemic arterial hypertension and pulmonary hypertension, both of which are related to the number of asthma deaths (Kaplan et al, 2020;Miethe et al, 2020;Branco et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Emerging Cell-Based Therapies in Chronic Lung Diseases: What About Asthma?

Cereta

Oliveira²,

Costa

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Asthma is a widespread disease characterized by chronic airway inflammation. It causes substantial disability, impaired quality of life, and avoidable deaths around the world. The main treatment for asthmatic patients is the administration of corticosteroids, which improves the quality of life; however, prolonged use of corticosteroids interferes with extracellular matrix elements. Therefore, cell-based therapies are emerging as a novel therapeutic contribution to tissue regeneration for lung diseases. This study aimed to summarize the advancements in cell therapy involving mesenchymal stromal cells, extracellular vesicles, and immune cells such as T-cells in asthma. Our findings provide evidence that the use of mesenchymal stem cells, their derivatives, and immune cells such as T-cells are an initial milestone to understand how emergent cell-based therapies are effective to face the challenges in the development, progression, and management of asthma, thus improving the quality of life.

show abstract

Obesity and asthma

Cited by 118 publications

References 105 publications

Evaluation of the obesity influence on the life quality in patients with bronchial asthma

Evaluation of the obesity influence on the life quality in patients with bronchial asthma

Linggan Wuwei Jiangxin formula ameliorates airway hyperresponsiveness through suppression of IL-1β and IL-17A expression in allergic asthmatic mice especially with diet-induced obesity

Emerging Cell-Based Therapies in Chronic Lung Diseases: What About Asthma?

Contact Info

Product

Resources

About